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Abstract: Worldwide, there are millions of people who have been diagnosed with osteoporosis, a bone
disease that increases the risk of fracture due to low bone mineral density and deterioration of bone
architecture. In the US alone, there are approximately ten million men and women diagnosed with
osteoporosis and this number is still growing. Diagnosis is made by measuring bone mineral density.
Medications used for the treatment of osteoporosis are bisphosphonates, denosumab, raloxifene, and
teriparatide. Recently, romosozumab has been added as well. In recent years, a number of advances
have been made in the field of diagnostic methods and the diverse treatment options for osteoporosis.
Despite these advances and a growing incidence of osteoporosis, there is a large group being left
undertreated or even untreated. This group of the under/untreated has been called the treatment
gap. Concerns regarding rare side effects of the medications, such as osteonecrosis of the jaw, have
been reported to be one of the many causes for the treatment gap. Also, this group seems not to be
sufficiently informed of the major benefits of the treatment and the diversity in treatment options.
Knowledge of these could be very helpful in improving compliance and hopefully reducing the gap.
In this paper, we summarize recent evidence regarding the efficacy of the various treatment options,
potential side effects, and the overall benefit of treatment.
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Osteoporosis is a disease with a high prevalence, which is a major public health burden
on our society. It is associated with a high incidence of fragility fractures. All osteoporotic
fractures increase morbidity, with hip and vertebrae fractures also leading to increased
mortality. Often osteoporotic fractures require admission to hospital, particularly hip
fractures, which account for 50% of osteoporotic fracture-related hospital admissions [1].
Once in hospital, these patients are also at a high risk of developing complications, such as
thrombosis (27%), urinary tract infections (12–61%), and pneumonia (7%) [1], exacerbating
their health problems. Thus, the treatment of osteoporosis and prevention of fractures are
vital for improving patients’ health and reducing the hospital burden.
The estimation is that ten million people in the US have osteoporosis and around
34 million are at risk. Worldwide, osteoporosis causes more than nine million fractures
annually. One in two women and one in five men who are 50 years of age will have
an osteoporotic fracture in their remaining lifetime. Among women, the ten-year risk of
any fracture increases from 9.8% at 50 years to 21.7% at the age of 80. The International
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Osteoporosis Foundation (IOF) reports an estimated one million quality-adjusted life years
(QALYs) were lost in 2017 due to fragility fractures in six European countries [2].
In addition, the estimated lifetime risk for 50-year-old women and men of coronary
disease is 39.2% and 51.7%, respectively. Cardiovascular risk management has been
commonplace for years now by lipid-lowering agents, antihypertensives and on indication
glucose-lowering therapies. Recent insights suggest that patients with a high cardiovascular
risk profile may also have preventive benefits from anti-osteoporotic drug treatment [3].
Osteoporotic fractures typically involve the hip, vertebrae, and the distal forearm.
However, because the effect of osteoporosis on the skeleton is systemic, the associated
increase in fracture risk substantially affects all skeletal sites [4]. Hip fractures are associated
with a greater reduction in quality of life than all other types of fracture, with excess
mortality risk. The incidence of a hip fracture increases exponentially with age in both
sexes. The estimated number of hip fractures worldwide will rise from 1.7 million in 1990
to 6.3 million in 2050 due to an increasing number of elderly people in the population [5].
The prevalence of a vertebral fracture increases progressively with age in both men and
women [6]. According to the European Vertebral Osteoporosis Study, one in eight women
and men aged 50 years had evidence of vertebral deformity [7]. In general, the incidence of
wrist fracture in men is low with no apparent increase with age [8]. Some studies showed
that in white women, the incidence of wrist fractures increases between the ages of 40 and
65 and then stabilizes [9].
Recent advances in drug development for the treatment of osteoporosis over the
last three decades have led to effective therapies for treating osteoporosis. Despite this,
osteoporosis is vastly undertreated. Concerns about rare side effects, current comorbidities,
and inadequate long-term efficacy of anti-resorptive drugs have led to an increase in
the number of untreated patients, referred to as an osteoporosis treatment gap [10]. The
treatment gap is considered such a major concern that multiple global health organizations,
such as the ASBMR, The Gerontological Society of America, and the Fragility Fracture
Network have issued global calls to tackle this crisis.
The purpose of this review is to summarize the evidence concerning the treatment
gap of osteoporosis. Particularly, which groups are at risk of osteoporosis and identifying
the factors underlying the treatment gap.
2. Definition & Diagnosis
Osteoporosis is defined by low bone density and deterioration of bone architecture,
which increase the risk of fractures. The diagnosis of osteoporosis is primarily determined by measuring bone mineral density (BMD) using noninvasive dual-energy X-ray
absorptiometry.
3. Who to Treat
Indications for treatment are mostly primary osteoporosis in the age-related variant
and/or sex hormone deficiency. These groups comprise mostly postmenopausal women.
Postmenopausal women are at a higher risk of fractures with twice the increased risk in
comparison to men [8]. The reduction of estrogen levels in women at menopause is one of
the most potent risk factors for the development of osteoporosis [11]. Treatment is generally
recommended in postmenopausal women with a BMD T-score of −2.5 or less, or with a
Fracture Risk Assessment Tool (FRAX) score indicating an increased risk of fracture, see
also Table 1.
With the FRAX, risk factors such as age, race, alcohol use, gender, body mass index,
smoking history, prior personal or parental history of fracture, use of glucocorticoids,
secondary osteoporosis, rheumatoid arthritis, and femoral neck BMD measurements are
included to predict the ten-year probability of hip fracture or other major osteoporotic
fracture. This tool can be used in conjunction with other diagnostic tools to identify
patients who are candidates for treatment. However, diagnosis and treatment of secondary
osteoporosis remain challenging as this often concerns premenopausal women or younger
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Category
T-Score
–1 or higher
Normal
Osteopenia
bone for
mass)
Between –1[12].
andManagement
–2.5
men who are
not usually(low
targeted
routine screening for osteoporosis
Osteoporosis
–2.5
or
lower
of secondary osteoporosis includes treatment of the underlying disease that causes bone
loss and specific osteoporosis therapy.
With the FRAX, risk factors such as age, race, alcohol use, gender, body mass index,
smoking
history,
prior
personal (WHO)
or parental
history
of for
fracture,
use ofbased
glucocorticoids,
Health
Organization
diagnostic
criteria
osteoporosis
on DXA bone
Table 1. World
secondary
osteoporosis,
rheumatoid
arthritis,
and
femoral
neck
BMD
measurements
are
mineral density.
included to predict the ten-year probability of hip fracture or other major osteoporotic
T-Score
fracture. This tool Category
can be used in conjunction with other diagnostic
tools to identify patients who are candidates
and
of secondary
Normal for treatment. However, diagnosis−
1 ortreatment
higher
osteoporosis
remain
challenging
as
this
often
concerns
premenopausal
Osteopenia (low bone mass)
Between −1 and −2.5 women or
younger men who are not usually targeted for routine screening for osteoporosis [12].
Osteoporosis
−2.5 or lower
Management of secondary osteoporosis includes treatment of the underlying disease that
causes bone loss and specific osteoporosis therapy.
Guidelines from
from the National Osteoporosis Foundation
Foundation recommend
recommend a daily intake
Guidelines
(from
supplements
and
diet
combined)
of
1200
mg
of
calcium
and
800–1000 IU
IU of
of vitamin
vitamin
(from supplements and diet combined) of 1200 mg of calcium and 800–1000
D,
regular
exercise,
fall-prevention
strategies,
avoidance
of
smoking
and
excess
D, regular exercise, fall-prevention strategies, avoidance of smoking and excess alcohol
alcohol
intake, and
and the
the use
use of
of anti-resorptive
or anabolic
agents, with
with reassessment
after two
two to
intake,
anti-resorptive or
anabolic agents,
reassessment after
to
five years
years for
for the
the treatment
treatment of
five
of osteoporosis
osteoporosis [13].
[13].
4. Pharmacological Treatment
4. Pharmacological Treatment
Currently, a broad range of pharmacological osteoporotic treatments is available to
Currently, a broad range of pharmacological osteoporotic treatments is available to
inhibit excessive bone resorption or to even increase bone formation. Figure 1 provides
inhibit excessive bone resorption or to even increase bone formation. Figure 1 provides
an overview of a selection of landmark studies per pharmacological agent throughout
an overview of a selection of landmark studies per pharmacological agent throughout
history [14–22].
history [14–22].

Figure 1. Timeline of randomized control trials in osteoporosis treatments discussed in this review.
Figure 1. Timeline of randomized control trials in osteoporosis treatments discussed in this review.

Osteoporotic
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Osteoporotic treatments
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with reductions
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mortality as
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morbidity
associated
with
osteoporotic
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The
most
commonly
used
anmorbidity associated with osteoporotic fractures. The most commonly used anti-resorptive
ti-resorptive
drugs are bisphosphonates
risedronate, ibandronate,
intradrugs are bisphosphonates
(alendronate,(alendronate,
risedronate, ibandronate,
intravenous forms
venous
forms and
pamidronate,
and[23].
zoledronate)
[23]. See
also Table 2 [24].
pamidronate,
zoledronate)
See also Table
2 [24].
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Table 2. Food and Drug Administration-Approved Pharmacological Interventions for Osteoporosis Treatment and Prevention.
Dose

Route of
Administration

Major Action

Type of Fracture
Reduction

FDA Indication

Alendronate

10 mg daily/70 mg
weekly

Oral

Anti-resorptive

Vertebral,
nonvertebral, hip

Treatment and
prevention

Risedronate

5 mg daily/35 mg
weekly/150 mg
monthly

Oral

Anti-resorptive

Vertebral,
nonvertebral, hip

Treatment and
prevention

Ibandronate

2.5 mg daily/150
mg monthly/3 mg
every three months

Oral/intravenous

Anti-resorptive

Vertebral

Treatment and
prevention

Zoledronic acid

5 mg yearly

Intravenous

Anti-resorptive

Vertebral,
nonvertebral, hip

Treatment and
prevention

60 mg every six
months

Subcutaneous

Anti-resorptive

Vertebral,
nonvertebral, hip

Treatment

60 mg daily

Oral

Anti-resorptive

Vertebral

Treatment and
prevention

Teriparatide

20 ug daily

Subcutaneous

Osteoanabolic

Vertebral,
non-vertebral

Treatment

Abaloparatide

80 ug daily

Subcutaneous

Osteoanabolic

Vertebral,
non-vertebral

Treatment

210 mg
monthly

Subcutaneous

Osteoanabolic/
anti-resorptive

Vertebral

Treatment

Class/Medication
Bisphosphonate

RANK Ligand
inhibitor
Denosumab
Selective estrogen
receptor
modulators
Raloxifene
Parathyroid
hormone analogs

Sclerostin
inhibitor
Romosozumab

Bisphosphonates are recommended as a first-line therapeutic option for the prevention
and treatment of osteoporosis in postmenopausal women and men. They inhibit bone
resorption by reducing the activity and viability of osteoclasts [25]. Bisphosphonates are
effective at reducing the fracture risk and increasing the bone turnover markers (BTMs)
and BMD at all skeletal sites. A meta-analysis that compared alendronate with a placebo
in older women with high fracture risk showed a 44% reduction in the risk of vertebral
fractures, displaying a hazard ratio of 0.56 [0.46–0.67], a 40% reduction in hip fracture risk
(HR, 0.60; 95% CI, 0.39 to 0.92), and a 17% reduction in nonvertebral fracture risk (HR,
0.83; 95% CI, 0.74 to 0.93) [26]. Bisphosphonates are estimated to prevent 80–5000 fragility
fractures for each atypical femur fracture possibly induced by treatment [13].
The human monoclonal antibody denosumab, which is a potent anti-resorptive drug
against receptor activator of NF-κB ligand (RANKL) [27], is recommended as an alternative
to bisphosphonates in the treatment of postmenopausal osteoporosis. Denosumab has been
shown to reduce fracture risk at all skeletal sites. Compared with a placebo, denosumab
showed a 68% reduction in the risk of vertebral fractures (HR, 0.32; 95% CI, 0.26 to 0.40),
a 39% reduction in the risk of hip fractures (HR, 0.61; 95% CI, 0.37 to 0.98), and a 19%
reduction in the risk of nonvertebral fractures (HR, 0.81; 95% CI, 0.69 to 0.95). After ending
the denosumab treatment, subsequent anti-resorptive agents like bisphosphonates should
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be given to prevent a rebound in bone turnover and to decrease the risk of rapid BMD loss
and an increased risk of fracture [28]. In a long-term treatment (up to ten years) FREEDOM
trial with denosumab, persistently low rates of new radiographic vertebral fractures (0.9%
to 1.86% per year), nonvertebral fractures (0.84% to 2.55% per year), and hip fractures
(0% to 0.61% per year) were observed in years four to ten, supporting its efficiency for a
long-term period [19].
Raloxifene is another anti-resorptive drug used for the prevention and treatment of
osteoporosis in women. It is a selective estrogen receptor modulator and is effective in
reducing the risk of vertebral fractures only (for 60-mg/d: RR, 0.7; 95% CI, 0.5–0.8; for
120-mg/d: RR, 0.5; 95% CI, 0.4–0.7) [20].
Unlike the anti-resorptive drugs that reduce bone resorption, the first anabolic therapy that stimulates bone formation is teriparatide. Teriparatide is a recombinant human parathyroid hormone analog that enhances osteoblastic activity to stimulate bone
formation on the bone surface. A dose of 20 ug/day of teriparatide given for up to
two years was found to decrease the risk of vertebral fractures by 65% (risk ratio [RR]
0.35, 95% CI 0.22–0.55) and non-vertebral fractures by 53% compared with a placebo
(0.47, 0.25–0.88) [21]. Teriparatide therapy should always be followed with an antiresorptive drug such as bisphosphonates to avoid bone density decline [29]. Abaloparatide is
another novel recombinant human parathyroid hormone analog. A meta-analysis that
compared abaloparatide with a placebo showed an 87% reduction in the risk of vertebral
fractures (HR, 0.13; 95% CI, 0.05 to 0.38) and a 46% reduction in the risk of non-vertebral
fractures (HR, 0.54; 95% CI, 0.31 to 0.96) [26].
Romosozumab is a new potential anabolic therapy that targets Wnt-B-catenin pathway inhibitors. Romosozumab is a humanized antibody that binds to and inhibits sclerostin, thereby preventing osteoblast maturation and function. In phase III clinical trials
romosozumab increased BMD at the lumbar spine and total hip by 13.3% and 6.8%, respectively, and reduced the risk of vertebral fracture by 73% compared with a placebo [30].
5. The Growing Gap in Treatment Options
Despite the great advances in the treatment of osteoporosis, a substantial proportion of
patients at high risk of fractures remain untreated, either because they are not given these
medications at all, or when prescribed, the patients are not taking them [31]. Hemlund et al.
have provided an extensive report estimating the treatment gaps in different European
countries [32]. Epidemiological inference was made by subtracting the size of the population exceeding the osteoporosis intervention threshold calculated by FRAX by the sales
numbers of anti-osteoporotic drugs corrected for non-adherence. This yielded treatment
gap proportions of 25 to 85% of patients estimated to be eligible for treatment but not
receiving it. This translates to a total in the EU of 12.3 million untreated individuals in
2010 [10]. An additional concern is the decrease of adherence per patient over time [33].
The most important reason for this gap is fear of rare side effects and concerns
regarding the long-term efficacy of the osteoporosis treatment. The main rare side effects
of concern for patients are atypical femur fractures and osteonecrosis of the jaw. Often,
patients decline treatment due to these concerns but do so without taking into consideration
the risk-benefit ratio of these drugs. Although these side effects are very rare and not
associated with all osteoporosis drugs, patient concerns about these risks are expanding to
all osteoporosis drugs.
This problem is exacerbated by the absence of clear evidence supporting the long-term
efficacy of anti-resorptive drugs, particularly bisphosphonates. Long-term use (over five
years) of bisphosphonates was found to be associated with increased risk of the rare side
effects of atypical femur fractures and osteonecrosis of the jaw. Previous reports indicated
that, unfortunately, the rates of osteoporosis medication use after hip fracture demonstrate
significant decline from 40.2% in 2002 to 20.5% in 2011 in the US [34].
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5.1. Rare Side Effects and Growing Treatment Gap
Although anti-resorptive drugs are effective in reducing the risk of fracture, concerns
about rare side effects have contributed to patients’ fear of taking osteoporosis medications,
leaving them at high fracture risk and increasing the osteoporosis treatment gap.
The evidence for bisphosphonates’ efficacy in reducing fracture risk comes from
strong clinical trials evaluating the effect of the drug over three to five years [14,16–18,35].
Although these studies report relatively few side effects of bisphosphonate use, they lack
information on the long-term effects. Long-term use of bisphosphonates, defined as more
than three years [36], was found to be associated with rare side effects, such as osteonecrosis
of the jaw [37] and atypical femoral fractures [36].
Osteonecrosis of the jaw is characterized by the exposure of the mandibular or maxillary bone. The absolute risk of bisphosphonate-associated osteonecrosis of the jaw was
estimated to range from 1 in 10,000 to 1 in 100,000 (or 0.001% to 0.01%) in osteoporosis
patients. Concerns about the long-term safety and efficacy of bisphosphonates have been
raised due to the increased risk of the rare side effects with long-term use (over five years).
The risk of osteonecrosis of the jaw in osteoporosis patients on long-term oral bisphosphonate therapy has been reported to be as high as 21 in 10,000 (or 0.21%) for patients
on over four years of therapy [38]. However, data from the Fracture Intervention Trial
Long-Term Extension (FLEX) showed that postmenopausal women with T scores (−2.0 to
−2.5) receiving alendronate for ten years had fewer vertebral fractures than women who
discontinued alendronate after five years (5.3% for placebo vs. 2.4% for alendronate; 95%
CI, 0.24–0.85) [15].
Atypical femur fractures are characterized by developing fractures in the subtrochanteric
region and along the femoral diaphyseal. Multiple studies have demonstrated this increased risk of atypical femur fractures among patients with bisphosphonate use; however,
the significance and severity of risk range from minimal (3.2/100,000/year) [39] to more
pronounced (113.1/100,000/year) [40,41]. The question of severity is key as the risk of
atypical femur fractures needs to be weighed against the reduction of fracture risk when
prescribing bisphosphonate treatment to patients. Recently, a large longitudinal study,
using data from electronic health records in California, investigated the risk of atypical
femur fracture in nearly 200,000 women using bisphosphonates. The women were followed
over a ten-year period to test the effect of bisphosphonate duration on the typical fracture
risk. The study found that longer bisphosphonate use is associated with atypical femur
fractures, with a duration of eight years or more displaying a hazard ratio of 43.51 (95%
CI, 13.70 to 138.15) and an incidence of 13.10/10,000/person yrs [42], in comparison to use
for less than three months. Additionally, the authors measured the risk of osteoporotic
and hip fractures due to bisphosphonate use in the same individuals. After three years of
bisphosphonate use, 149 hip fractures were prevented, while only two atypical fractures
occurred [42]. The authors conclude that the decreases in osteoporotic and hip fractures
gained by bisphosphonate use far outweigh the increased risk of atypical fractures. The
results and conclusion are in line with a previous, albeit smaller study, conducted by R.M.
Dell and colleagues [40].
Also, oral forms of bisphosphonates can cause upper gastrointestinal irritation, which
may include heartburn, indigestion, esophageal erosion, and esophageal ulcer.
The human monoclonal antibody denosumab is well-tolerated, but adverse effects
have been observed including hypocalcemia, serious infections, skin rash, and musculoskeletal pain.
The use of the selective estrogen receptor modulator raloxifene is commonly associated
with increased vasomotor symptoms. It increases the overall incidence of hot flushes by
+6.3% compared to a placebo [43]. Although raloxifene reduces breast cancer risk [44],
it is associated with an increased risk of venous thromboembolism (RR, 3.1; 95% CI,
1.5–6.2). There was a black-box warning about a risk of osteosarcoma associated with the
recombinant human PTH hormone analog teriparatide treatment. The FDA limited the
treatment duration of teriparatide to two years due to the development of osteosarcoma
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in rats treated with high doses of teriparatide [45]. Of note, a subsequent post-marketing
surveillance study of patients treated with teriparatide has not found a causal association
between osteosarcoma and the use of teriparatide in humans [46]. However, in November
2020, the FDA approved the removal of the box warming regarding osteosarcoma for a
longer duration of treatment (more than two years) in patients who remain at or return
to a high risk of fracture. Therefore, this should help to reduce the uncertainty relating
to the use of teriparatide and the increased risk of osteosarcoma, and should be useful
to both clinicians and patients as it considers the possible risks vs. potential benefits of
treating osteoporosis patients at high risk of fracture. The adverse effects of teriparatide
included greater rates of leg cramps and dizziness compared to a placebo [21]. The second
recombinant human PTH hormone analog abaloparatide has the same box warning as
teriparatide. The most common adverse events seen with the use of abaloparatide were
dizziness, fatigue, headache, nausea, palpitations, and postural hypotension [47].
The anti-sclerostin antibody romosozumab might increase the risk of cardiovascular
complications. Romosozumab was associated with increased adjudicated serious cardiovascular events (4.9% vs. 2.5%), cardiac ischemic events (1.8% vs. 0%), and cerebrovascular
events (1.8% vs. 1.2%) compared with the control group [48].
Many guidelines for the treatment of osteoporosis recommend the treatment of postmenopausal women and men that are at high risk of fractures, especially those who have
experienced a recent fracture. However, because of the side effects of osteoporotic treatment,
patient-specific clinical factors should be taken into account. Due to concerns about renal
toxicity, bisphosphonate should be avoided in patients whose estimated glomerular filtration rate (eGFR) <30 to 35 mL/min [28]. Nonetheless, as long as a minimum of a 15-min
infusion time is maintained and the patient is well-hydrated, there has been no evidence of
loss of renal function with zoledronic acid in randomized clinical trials for osteoporosis.
Miller et al. reviewed the trials and reported cases of bisphosphonate-associated renal
damage and found only lasting side effects in zoledronic acid-associated renal impairment,
which involved the dosing regimen of zoledronic acid 4 mg once every three to four weeks
in cancer patients, which is a higher dose than the 5 mg once-per-year dosage for patients
with osteoporosis. Moreover, cancer patients (e.g., patients with multiple myeloma or
some advanced solid tumors) are known to be at risk of renal failure from compromised
kidney function and hypercalcemia. Still, in practice, some clinicians administer reduced
dosages of 3 or 4 mg of zoledronate yearly in osteoporosis patients with chronic kidney
insufficiency in the absence of cancer. In contrast to the bisphosphonates, denosumab may
be administered to patients with CKD and those with eGFRs of ≤35 mL/min/1.73 m2 . Yet,
because denosumab can cause hypocalcemia, patients with low calcium levels should be
corrected before treatment initiation. In patients who have a history of or active venous
thromboembolism, raloxifene should be avoided. Patients with Paget’s disease of the
bone, unexplained alkaline phosphatase elevations, prior skeletal radiotherapy, primary or
metastatic bone malignancy, or hypercalcemic disorders, such as primary hyperparathyroidism, should avoid using teriparatide. Abaloparatide should be avoided in patients
with pre-existing hypercalcemia and those with an underlying hypercalcemic disorder, like
primary hyperparathyroidism. In summary, from the above, we see that specific patient
populations merit specific treatment considerations; nonetheless, most often, an alternative
treatment option is available.
5.2. Underestimation of the Fracture Risk and Growing Treatment Gap
Some reports found that clinical calculators including FRAX may underestimate
fracture risk in over half of patients [49]. This may be due to a lack of some factors known
to be associated with fracture risk, such as falls [24]. Also, FRAX has not been validated
for use in patients receiving osteoporotic treatment and will underestimate fracture risk
in these patients. FRAX does not correctly calculate fracture risks with ages outside the
stated range of 40 to 90 years. Also, one can only enter femoral neck BMD because it has
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not been confirmed for use with total hip or lumbar spine BMD. Finally, it does not give
recommendations on whom to treat nor on exact treatment choices.
6. Bisphosphonate Use, Mortality, and Vascular Calcification
The reduction in osteoporotic fractures may provide substantial benefits in terms of
saving lives, reducing morbidity, and reductions in healthcare costs. Many studies have
reported that bisphosphonate use may, in addition, decrease the risk of mortality [50–54].
However, it is unclear whether the effect is causal or merely confounded by better overall
health in bisphosphonate-treated patients than in non-treated patients. Further, no clearly
established bone-related mechanisms have been found to explain why greater BMD may
decrease mortality independent of fracture risk. However, there is an intriguing connection
between BMD and vascular calcification, which may provide a mechanism of effect on
mortality. Vascular calcification shows some similarities with ossification and the frequent
co-occurrence of increased vascular calcification with osteoporosis is referred to as the
calcification paradox [55].
Several studies have shown an association between low BMD and high coronary
arterial calcification, especially in women [56,57]; however, others have failed to replicate
the finding [58]. It is thought that bisphosphonates may act to reduce arterial calcification
by promoting the deposition of calcified tissues as BMD. This could be a potential benefit
in cardiovascular diseases. Several meta-analyses and systematic reviews have been
conducted to investigate the potential relationship. The studies conducted recently confirm
that arterial calcification is reduced with bisphosphonate use. However, while some studies
indicate that there is no beneficial effect on cardiovascular outcomes [59], others report
a reduction in cardiovascular mortality and all-cause mortality [3]. A recent prospective
cohort study involving nearly 83,000 bisphosphonate users indicates that higher treatment
adherence is associated with better cardiovascular outcomes, with those in the strictest
adherence displaying a hazard ratio of 0.75 [0.71–0.81] [60]. These studies provide evidence
of a potential mechanism between arterial calcification and BMD, which requires further
exploration. However, if valid, it could provide further justification for the intervention
of osteoporotic patients and even patients with moderately compromised BMD with high
cardiovascular risk with bisphosphonates.
7. Glucocorticoid-Induced Osteoporosis
Glucocorticoids have been in use for many decades to treat a variety of inflammatory
conditions [61–63]. The earliest reports on the increased fracture risk associated with exposure to these drugs date from the mid-20th century [64–66], and currently, glucocorticoidinduced osteoporosis is the leading cause of secondary osteoporosis [67]. Bone loss already
occurs in the first months of treatment with glucocorticoids in a dose-dependent manner.
Although the effects of glucocorticoids on bone remodeling are manifold, they eventually
lead to stimulation of osteoclast activity and suppression of osteoblasts. Another indirect
effect of glucocorticoid treatment is, for example, a decrease in muscle strength, thereby
elevating the fall risk and thus the fracture risk [67,68].
With the advancement of osteoporosis treatment, prevention of glucocorticoid-induced
osteoporosis became possible. Prophylactically prescribing osteoporosis treatment to patients receiving glucocorticoids has been proven successful in diminishing the fracture
risk, most notably of vertebral fractures [68–70]. Nonetheless, many reports starting in the
1990s found up to 95% of patients on glucocorticoids did not receive proper osteoporosis
prophylaxis [71–73].
Recent years have seen a number of guidelines, which include the 2017 UK clinical
guideline for the prevention and treatment of osteoporosis [74] and 2017 ACR guideline
for the prevention and treatment of glucocorticoid-induced osteoporosis [75], using the
framework laid down by the International Osteoporosis Foundation and the European
Society of Calcified Tissues [76]. Basically, these guidelines provide a way to assess the
(increased) fracture risk associated with glucocorticoid treatment, which can be used to
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decide whether or not to prescribe osteoporosis prophylaxis. Patients on glucocorticoids
aged over 70 years, with previous fractures, or receiving ≥7.5 mg prednisolone QD for
more than three months are generally expected to pass the treatment threshold [76]. These
conditions appear in some of the older guidelines, as well.
Additionally, Naunton et al. found that an educational program improved adherence
to guidelines and significantly increased the proportion of patients on glucocorticoids
receiving prophylactic treatment [77]. Carter also reported increased compliance with the
2017 guidelines from 25 to 92% in a UK general practice following education and active
identification of patients at risk of glucocorticoid-induced osteoporosis [78].
Despite the improvements in prescribing prophylaxis for glucocorticoid-induced
osteoporosis following the introduction of guidelines and educational programs, some
patients may still be treated suboptimally. Future research will hopefully identify the
factors causing this specific treatment gap.
8. Future Directions
Fractures caused by osteoporosis are a major cause of morbidity and mortality, especially among elderly people. Despite advances in fracture risk assessment and osteoporosis
treatment to reduce fracture risk, only a minority of patients with osteoporosis are treated.
Most hip fracture patients lose the ability to live independently. Hip fractures have serious
consequences in terms of reduced function and increased disability. The loss of mobility
and independence, combined with admission to a nursing home following a hip fracture,
is a real fear for older people. Therefore, it is important for patients with osteoporosis to
understand that treating osteoporosis can reduce the risk of hip fractures, which, in turn,
can reduce the risk of loss of independence and admission to nursing homes.
The rare side effects of anti-resorptive therapies have become a major concern for
patients with osteoporosis and contribute to the treatment gap. Several steps can be taken
to address this issue: improved education of both patients and doctors on the side effects
vs. the benefits of osteoporosis drugs, increased awareness of newly-developed drugs
that lack these side effects among patients and doctors, and routinely following up and reevaluating patients, such as through fracture liaison services; also, identification of patients
in high-risk groups such as the aforementioned glucocorticoid-induced osteoporosis.
Another step could be screening for atypical femoral fractures using extended femur
scans by DXA to monitor patients on bisphosphonates and denosumab [79].
Hopefully, future research regarding pharmacogenomic markers will also aid in
identifying patients at increased risk of atypical femur fractures, which will probably help
in narrowing the treatment gap.
9. Conclusions
Osteoporosis-related fractures are associated with excess morbidity, mortality, and
healthcare costs. Recent decades have seen a dramatic transformation in our understanding
of osteoporosis epidemiology, pathophysiology, diagnosis, and treatment. The availability
of multiple novel therapeutic options for fracture prevention and treatment may reduce the
burden of fracture on our societies. However, the fear of rare adverse effects of osteoporotic
medications and concerns regarding their long-term efficacy are increasing the osteoporosis
treatment gap. This gap could be narrowed by improved awareness of both the patient and
doctor on the risks of not receiving the treatment and the risks and benefits of osteoporotic
treatment. Moreover, there is still an important need to find ways to improve patients’
acceptance of these effective medications and to continue developing new drugs that do
not cause these side effects, with long-term efficacy. Such changes could result in a true
shift of this potentially age-related disease.
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